BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

PURPOSE: Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and nat...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Oncol
Main Authors: Woyach, Jennifer A., Ruppert, Amy S., Guinn, Daphne, Lehman, Amy, Blachly, James S., Lozanski, Arletta, Heerema, Nyla A., Zhao, Weiqiang, Coleman, Joshua, Jones, Daniel, Abruzzo, Lynne, Gordon, Amber, Mantel, Rose, Smith, Lisa L., McWhorter, Samantha, Davis, Melanie, Doong, Tzyy-Jye, Ny, Fan, Lucas, Margaret, Chase, Weihong, Jones, Jeffrey A., Flynn, Joseph M., Maddocks, Kami, Rogers, Kerry, Jaglowski, Samantha, Andritsos, Leslie A., Awan, Farrukh T., Blum, Kristie A., Grever, Michael R., Lozanski, Gerard, Johnson, Amy J., Byrd, John C.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2017
נושאים:
ORIGINAL REPORTS
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455463/
https://ncbi.nlm.nih.gov/pubmed/28418267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.2282
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים